Enjoy complimentary customisation on priority with our Enterprise License!
The eczema therapeutics market share is expected to increase by USD 4.36 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 9.6%.
This market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers indications (atopic dermatitis, contact dermatitis, and others) and geography (North America, Europe, Asia, and ROW). The market report also offers information on several market vendors, including AbbVie Inc., Alliance Pharma Plc, Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bausch Health Co Inc, Bayer AG, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd, Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Foundation for Medical Education and Research, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.
Download Report Sample to Unlock the Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post-COVID-19 era. The high prevalence of atopic dermatitis is notably driving the market growth, although factors such as side effects associated with corticosteroids may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the eczema therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Eczema Therapeutics Market Driver
The high prevalence of atopic dermatitis is a key factor driving the global market growth. There is a high prevalence of eczema globally. Eczema can be caused due to several factors, including exposure to allergens such as peanuts, pollen, or pet dander; skin irritants such as household cleaners, some fabrics, or soaps; stress; dry skin; and infections. Such a large patient pool presents a significant opportunity for the growth of the market. The large patient cohort requires multiple visits to dermatologists and numerous medications for the treatment of eczema, which consequently drives market growth. Asia also hosts a huge patient population with atopic dermatitis, with China, India, and Japan being the top three revenue contributors to the market in the region. Developing countries such as India and China present promising market opportunities due to their large population.
Key Eczema Therapeutics Market Trend
Business strategies are a key trend impacting global market growth. The vendors operating in the market have been implementing different strategies to expand their product portfolio, especially over the last five years, which have significantly impacted the global skincare market. They are undergoing different business strategies such as M&A and technology partnerships to increase their market presence and the sales of their eczema product range. Such strategies may provide an opportunity for vendors to increase their profit margins. in September 2020, Kymera Therapeutics Inc. entered into a multi-program strategic collaboration with Sanofi to develop and commercialize its first-in-class protein degrader therapy targeting IRAK4 in patients with immune-inflammatory diseases, including atopic dermatitis. Such initiatives will strengthen the growth of the market focus during the forecast period.
Key Eczema Therapeutics Market Challenge
Side effects associated with corticosteroids will be a major challenge impacting negatively the global market growth. Corticosteroids are one of the most commonly prescribed medications for all eczema indications, including atopic dermatitis. Some of the local side effects of corticosteroids in patients with eczema may include thinning of the skin (atrophy), skin thickening (lichenification), darkening of the skin, and stretch marks (striae). In some cases, they may even trigger or worsen skin disorders such as perioral dermatitis. Some of the systemic side effects of topical corticosteroids include fluid accumulation in the legs, high blood pressure, bone damage, and Cushing's syndrome. These factors discourage the use of corticosteroids for long-term eczema treatment, resulting in low adoption among patients, which, in turn, impedes the growth of the global market.
This market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global eczema therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the market during the forecast period.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the market encompasses successful business strategies deployed by the key vendors. The market is fragmented and the vendors are deploying growth strategies such as organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
42% of the market’s growth will originate from North America during the forecast period. The US is the key market for eczema therapeutics in North America. Market growth in this region will be faster than the growth of the market in regions.
The market is expected to demonstrate promising growth during the forecast period due to favourable reimbursement policies, growing partnerships of key vendors with contract research organizations in emerging markets, and high smart healthcare expenditure will facilitate the market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of COVID-19 affected all countries in North America, especially the US, in 2020. It also hurt the market in North America. As of May 27, 2021, more than 32.2 million COVID-19 cases were reported in the US. A rise in the number of COVID-19 cases in the first quarter of 2021 led to a partial lockdown in several countries, including Canada and Mexico. Thus, as per the government measures and guidelines to contain the spread of COVID-19, healthcare facilities either provided non-urgent treatments and clinical visits in a limited capacity or completely shut down operations in countries across the region.
To gain further insights on the market contribution of various segments Request a PDF Sample
The market share growth in the atopic dermatitis segment will be significant during the forecast period. The segment is also projected to grow at the fastest rate during the forecast period due to a strong pipeline landscape, with several promising product candidates in various stages of clinical development.
This report provides an accurate prediction of the contribution of all the segments to the growth of the market size and actionable market insights on the post-COVID-19 impact on each segment.
Atopic Dermatitis Drugs Market- The market size is estimated to grow at a CAGR of 9.28% between 2022 and 2027. The market size is forecast to increase by USD 4,720.19 million.
|
Eczema Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 9.6% |
|
Market growth 2022-2026 |
$ 4.36 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
9.0 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 42% |
|
Key consumer countries |
US, Canada, Germany, UK, and France |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
AbbVie Inc., Alliance Pharma Plc, Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bausch Health Co Inc, Bayer AG, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd, Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Foundation for Medical Education and Research, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Indication
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
